Journal of Translational Medicine (Mar 2022)

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

  • Bing-Tao Zhai,
  • Huan Tian,
  • Jing Sun,
  • Jun-Bo Zou,
  • Xiao-Fei Zhang,
  • Jiang-Xue Cheng,
  • Ya-Jun Shi,
  • Yu Fan,
  • Dong-Yan Guo

DOI
https://doi.org/10.1186/s12967-022-03329-3
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 24

Abstract

Read online

Abstract Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels in malignant tumours. uPAR is closely related to the invasion and metastasis of malignant tumours, plays important roles in the degradation of extracellular matrix (ECM), tumour angiogenesis, cell proliferation and apoptosis, and is associated with the multidrug resistance (MDR) of tumour cells, which has important guiding significance for the judgement of tumor malignancy and prognosis. Several uPAR-targeted antitumour therapeutic agents have been developed to suppress tumour growth, metastatic processes and drug resistance. Here, we review the recent advances in the development of uPAR-targeted antitumor therapeutic strategies, including nanoplatforms carrying therapeutic agents, photodynamic therapy (PDT)/photothermal therapy (PTT) platforms, oncolytic virotherapy, gene therapy technologies, monoclonal antibody therapy and tumour immunotherapy, to promote the translation of these therapeutic agents to clinical applications.

Keywords